Has David Wilson received payments from drug or device companies?

Yes. Drug and device makers reported $22,222 in general payments to David Wilson across 451 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Wilson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Wilson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Wilson

Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1922030832

Payments from drug & device makers

$22,222in general payments, 2019–2025

Across 451 payments — averaging $49.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$12K
Johnson & Johnson$3K
AstraZeneca$1K
Amarin Pharma, Inc.$632
AbbVie$518
Sanofi-aventis U.S. LLC$444
plus $4K from 38 others

What the payments were for

Consulting fees$3,25015%
Speaking & faculty fees$9,76044%
Travel & lodging$9494%
Food & beverage$8,25537%
Education$80%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	50	$11,742
Johnson & Johnson	17	$3,407
AstraZeneca(2 entities)	63	$1,283
Amarin Pharma, Inc.	28	$632
AbbVie	33	$518
Sanofi-aventis U.S. LLC	20	$444
Amgen(2 entities)	23	$443
Boehringer Ingelheim	27	$422
Abbott	15	$317
Medtronic(2 entities)	16	$286
Novo Nordisk	18	$276
Mannkind Corporation	12	$210
Merck	13	$186
Clarus Therapeutics Inc.	3	$150
Esperion Therapeutics, Inc.	9	$143
Radius Health, Inc.	7	$141
Dexcom, Inc.	8	$131
Endo Pharmaceuticals Inc.	7	$121
Insulet Corporation	5	$113
Antares Pharma, Inc.	6	$107
BD	6	$104
Zealand Pharma US, Inc.	6	$100
Stryker	3	$93
Companion Medical, Inc.	7	$91
Corcept Therapeutics	6	$88
Amneal Pharmaceuticals LLC	5	$71
Acerus Pharmaceuticals Corporation	5	$69
Kowa Pharmaceuticals America, Inc.	5	$65
IBSA Pharma Inc.	4	$63
Shire North American Group Inc	3	$54
Valeritas, Inc.	3	$44
Pfizer	2	$43
Bayer	2	$40
Recordati_rare_diseases_inc.	2	$39
Althera Pharmaceuticals LLC	2	$31
Roche Diabetes Care, Inc.	2	$28
Ipsen Biopharmaceuticals, Inc	1	$22
Lifescan, Inc.	1	$19
Eisai Inc.	1	$17
Boston Scientific	1	$16
Ultragenyx Pharmaceutical Inc.	1	$15
Takeda Pharmaceuticals U.S.A., Inc.	1	$14
Tandem Diabetes Care, Inc.	1	$13
Ascensia Diabetes Care US Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TRULICITY$11,149
INVOKANA$3,060
JATENZO$348
Vascepa$253
PRALUENT$118

How this compares

$22,222 in reported general payments places this provider in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Other endocrinology, diabetes & metabolism in Fort Worth

Anjanette TanFort Worth$2.5M
Chris BajajFort Worth$785K
Julio RosenstockDallas$24.9M
Michelle WelchShavano Park$17.3M
Maria CabanillasHouston$16.4M
Sumana GangiMesquite$13.2M
Damaris VegaHouston$12.3M
Mark KipnesSan Antonio$10.3M
Amer Al KaradshehHouston$8.8M
Ildiko LingvayDallas$8.2M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →